Article
Real-world emergence of nirsevimab resistance in breakthrough infections with respiratory syncytial virus-B: a multicentre observational study in France.
The Lancet. Microbe - 1 Jul 2026
Fourati Slim, Reslan Alawiya, Bourret Jérôme, Casalegno Jean-Sébastien, Rahou Yannis, Softic Laurent, Chollet Lionel, Trémeaux Pauline, Imbert-Marcille Berthe-Marie, Pillet Sylvie, Veyrenche Nicolas, Boudet Agathe, Deroche Luc, Burrel Sonia, Mouna Lina, Cocherie Theophile, Schnuriger Aurélie, Pronier Charlotte, Handala Lynda, Brodard Véronique, Gallais Floriane, Larrat Sylvie, Regueme Alexandre, Dossou Nefert Candace, Henry Amandine, Gault Elyanne, Hartard Cédric, Brichler Ségolène, Moisan Alice, Avettand-Fenoel Véronique, Lefeuvre Caroline, Engelmann Ilka, Castelain Sandrine, Mirand Audrey, Salmona Maud, Jaffar-Bandjee Marie-Christine, Ader Mohamed, Seng Sarah, Cappy Pierre, Rodriguez Christophe, Ly Arnaud, Dos Santos Georges, Schwartz Olivier, Petiot Chloé, Planas Delphine, Ibraim Samar Berreira, Da Silva Kévin, Recoing Amélie, Pawlotsky Jean-Michel, Lemoine Frédéric, Audureau Etienne, Rameix-Welti Marie-Anne
Abstract excerpt
BACKGROUND: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in infants. Nirsevimab, a long-acting monoclonal antibody targeting a conserved epitope on the prefusion F protein (site Φ), has shown high efficacy in clinical trials and early real-world studies. Although widespread resistance has not been reported, concerns remain about the emergence of escape variants,...
Read the complete abstract on PubMed